Copaxone And Complex Generics: Difficult-To-Copy Does Not Mean Impossible
This article was originally published in RPM Report
Executive Summary
FDA’s approval of the first ANDA for an MS therapy signals the agency’s determination to find a way to get generic versions of complex drugs to market. What if any lessons does that hold for biosimilars?